TOP10 reimbursement value in Poland – November 2024

?? Updated November 2024 #DGL bulletin data

?? As of November 2024, the cumulative #reimbursement amount has reached nearly PLN 22 billion, reflecting an increase of PLN 4.6 billion compared to the same period last year.

?? The ranking of the top three products in the overall market remains unchanged. However, #Spinraza has dropped three positions, now ranking 9th. Meanwhile, #Lynparza has climbed to 7th place, with a cumulative reimbursement amount of PLN 251 million this year—marking a year-over-year growth of 48.4%. Notably, brands within the TOP10 in the foodstuffs category command 88.7% of the market share. A standout performer, Neocate Syneo, has recorded a staggering 616.0% year-over-year increase in reimbursement (PLN 15.3 million this year compared to PLN 2.1 million in the same period last year).

?? Within the drug programmes, #Kaftrio has surged to 4th place despite experiencing a -16.7% year-over-year decline in reimbursement.

?? On the outpatient list, #Accu-Chek has made its debut in the TOP10, securing the 10th position. Meanwhile, #Ozempic has climbed to 5th place, boasting a remarkable year-over-year reimbursement growth of 106.1%, with a cumulative reimbursement of PLN 162.8 million this year.

?? Collectively, as of November 2024, the cumulative reimbursement for the TOP10 brands has reached PLN 3.6 billion. The overall market has seen a year-over-year increase of PLN 965 million, representing a robust growth rate of 36.6%.

You can find more data in our IDA TOP10 report: https://app.powerbi.com/view?r=eyJrIjoiZGI3MDlkYWEtZDhmZi00MmIxLTlkNDctZTk3NjgyZWQyMjUyIiwidCI6IjFhYjJiNGUwLWE4ZmUtNGQ3OS1hY2Q1LTk2NzhlMThiN2IxOSIsImMiOjl9&embedImagePlaceholder=true